NY-AQARA
Aqara, a provider for smart home products, announced the launch of the Aqara Roller Shade Driver E1, a retrofit roller shade controller to automate the existing beaded chain roller shades. The roller shade driver fits beaded cord roller shades with the bead thickness of 3 - 6 millimeter, and works with both plastic and metal beads. The driver has been available on Amazon UK starting from September 22, 2021, and it is expected to land on Amazon France in the next few weeks. It will also be made available via authorized Aqara retailers in Europe and Asia in the following months.
Shades are necessary for almost all homes, as they block harmful UV rays, save energy (for ACs and lights) and protect privacy. Automated shades save users the trouble of manually controlling the shades day in and day out, while helping to cut energy bills and enhance indoor comfort.
The Roller Shade Driver E1 provides a quick, easy and cost-effective way to automate the existing roller blinds. The installation is simple, as it does not require dedicated wiring. Just screw the device to the wall, insert the beaded chain of the roller shade, and the driver will be ready to be connected. The roller shade driver can be charged wirelessly from the built-in battery (2-month battery life per charge1 ), or be plugged into a constant power supply via the provided USB Type-C cable, offering high installation flexibility to users. Four adapters for different types of beaded chains are provided, so that the driver could work with a majority of beaded chain roller shades.
The roller shade driver supports the latest Zigbee 3.0 protocol, and it can be bound with an Aqara hub2 to work with other Aqara child devices, enabling smart home scenes and automations. It is also compatible with major ecosystems including Apple HomeKit, Amazon Alexa, Google Home, and more3 .
With this roller shade driver, users can not only control the roller shades by wireless remote switches and voice commands, they can also configure home automations such as rolling down the blinds automatically when the sun is too bright, or when the user goes to bed at nights.
To celebrate the launch, Aqara now offers a 15% discount for the Roller Shade Driver E1 on its Amazon UK store with the promo code: RSDE1PR1, and the offering will be valid through September 24, 2021.
Moreover, the Roller Shade Driver E1 will be released to the Aqara brand store on Amazon.fr in the next few weeks. It is also expected to be made available in various European and Asian countries via authorized Aqara retailers in the following months. Please check with the regional retailer(s) for product availability.
For more details of the roller shade driver, please visit our website .
1 Based on the assumption of rolling up and down a roller shade of 1.8m*1.8m once a day
2 A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required.
3 Integration with some third-party ecosystems may be unavailable by the time of the launch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom